Home > Press > GenScript will launch services with GANP® technology for World Wide market excluding Japan
Abstract:
GenScript Corporation signed a worldwide (excluding Japan) non-exclusive license agreement with TransGenic Inc. through which GenScript Corporation is authorized to use GANP® mice from TransGenic Inc. to produce high-affinity antibodies to scientists.
GANP (Germinal Center Associated Nuclear Protein) is a protein discovered by Dr. Nobuo Sakaguchi at Kumamoto University to be over-expressed in B-cells centered in embryo. Research suggested that GANP is important in the reconstruction of antibody genes. Transgenic mice which express high level of GANP can be used to produce antibodies with a high affinity.
"This technology will tremendously improve the quality of our antibody products in terms of specificity, affinity and epitope diversity." commented David Chang, director of GenScript's Antibody Department.
GenScript has developed a state-of-the-art antibody production platform to meet different customers' needs, including OptimumAntigenTM design tool, T-MaxTM adjuvant, and nanotechnology for antigen preparation. Her animal facility was accredited by AAALAC and OLAW. With access to GANP® Mouse Technology, antibodies generated from GenScript can potentially be used for diagnostic and therapeutic purposes because of higher affinity and higher specificity.
####
About GenScript
GenScript is a contract research organization (CRO) specialized in biological research and early-phase drug discovery services. Its service portfolio includes bio-reagent services, assay development & screening, lead optimization, and antibody drug development. The renowned one-stop bioreagent services include custom gene synthesis and molecular biology, custom protein expression and purification, custom peptide synthesis, antibody production, and custom cell line development. Headquartered in Piscataway, New Jersey, GenScript is the largest gene synthesis supplier in the USA, with subsidiaries in France, Japan, and China.
For more information, please click here
Contacts:
Sally Wang
Executive Vice President
GENSCRIPT USA Inc.
1-(732) 885-9188
Copyright © GenScript Corporation
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
Alliances/Trade associations/Partnerships/Distributorships
Chicago Quantum Exchange welcomes six new partners highlighting quantum technology solutions, from Chicago and beyond September 23rd, 2022
University of Illinois Chicago joins Brookhaven Lab's Quantum Center June 10th, 2022
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||